Search details
1.
Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy.
Ann Surg Oncol
; 31(6): 3872-3879, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38353798
2.
Real-world outcomes of adjuvant immunotherapy candidates with upper tract urothelial carcinoma: results of a multicenter cohort study.
Int J Clin Oncol
; 29(1): 55-63, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-37863996
3.
Prostate cancer and liquid biopsies: Clinical applications and challenges.
Int J Urol
; 2024 Mar 29.
Article
in English
| MEDLINE | ID: mdl-38551314
4.
Prognostic significance of subclassifying pathological T3 upper tract urothelial carcinoma: Results from a multicenter cohort study.
Int J Urol
; 31(2): 125-132, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-37828777
5.
Validation study on the 2 mm diameter cutoff in lymph node-positive cases following radical prostatectomy in accordance with the AJCC/UICC TNM 8th edition: Real-world data analysis from a Japanese cohort.
Int J Urol
; 2024 Feb 29.
Article
in English
| MEDLINE | ID: mdl-38424729
6.
The clinical impact of ureteroscopy for upper tract urothelial carcinoma: A multicenter study.
Int J Urol
; 31(4): 394-401, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38151321
7.
Long-term outcomes of radical prostatectomy versus low-dose-rate brachytherapy in patients with intermediate-risk prostate cancer: Propensity score matched comparison.
Prostate
; 83(2): 135-141, 2023 02.
Article
in English
| MEDLINE | ID: mdl-36176043
8.
Comparison of neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma in real-world practice: a multicenter retrospective study.
Jpn J Clin Oncol
; 53(12): 1208-1214, 2023 Dec 07.
Article
in English
| MEDLINE | ID: mdl-37647644
9.
Comparison of outcomes in high-risk prostate cancer patients treated with low-/high-dose-rate brachytherapy plus external beam radiotherapy.
Int J Clin Oncol
; 28(5): 698-706, 2023 May.
Article
in English
| MEDLINE | ID: mdl-36814038
10.
The prognostic significance of the clinical T stage and Grade Group in patients with locally advanced prostate cancer treated via high-dose-rate brachytherapy and external beam radiation.
Int J Clin Oncol
; 28(8): 1092-1100, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-37227547
11.
Clinical characteristics of secondary bladder cancer developing after low-/high-dose-rate brachytherapy to treat localized prostate cancer.
Int J Clin Oncol
; 28(9): 1200-1206, 2023 Sep.
Article
in English
| MEDLINE | ID: mdl-37432614
12.
Patients with PSA below 0.2 ng/mL at 8 years post high-dose-rate brachytherapy have an extremely low risk of subsequent recurrence.
Int J Urol
; 30(12): 1147-1154, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-37650359
13.
Radiotherapy plus androgen deprivation therapy for prostate-specific antigen persistence in lymph node-positive prostate cancer.
Cancer Sci
; 113(7): 2386-2396, 2022 Jul.
Article
in English
| MEDLINE | ID: mdl-35485635
14.
Clinical significance of unfavorable findings in intermediate-risk prostate cancer patients for predicting treatment outcomes after contemporary, dose-escalated multimodal radiotherapy.
Prostate
; 82(4): 433-441, 2022 03.
Article
in English
| MEDLINE | ID: mdl-34914134
15.
Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR.
Cancer Immunol Immunother
; 71(2): 461-471, 2022 Feb.
Article
in English
| MEDLINE | ID: mdl-34235546
16.
Prognostic value of PSA bounce after definitive radiotherapy revisited.
Int J Clin Oncol
; 27(2): 411-417, 2022 Feb.
Article
in English
| MEDLINE | ID: mdl-34677737
17.
How long is long enough to secure disease control after low-dose-rate brachytherapy in combination with other modalities in intermediate-risk, localized prostate cancer?
Int J Clin Oncol
; 27(1): 184-193, 2022 Jan.
Article
in English
| MEDLINE | ID: mdl-34599724
18.
Loss of HIF1A From Pancreatic Cancer Cells Increases Expression of PPP1R1B and Degradation of p53 to Promote Invasion and Metastasis.
Gastroenterology
; 159(5): 1882-1897.e5, 2020 11.
Article
in English
| MEDLINE | ID: mdl-32768595
19.
Prognostic model with alkaline phosphatase, lactate dehydrogenase and presence of Gleason pattern 5 for worse overall survival in low-risk metastatic hormone-sensitive prostate cancer.
Jpn J Clin Oncol
; 51(11): 1665-1671, 2021 Nov 01.
Article
in English
| MEDLINE | ID: mdl-34296282
20.
Blood platelet volume predicts treatment-specific outcomes of metastatic castration-resistant prostate cancer.
Int J Clin Oncol
; 25(9): 1695-1703, 2020 Sep.
Article
in English
| MEDLINE | ID: mdl-32488548